We are pleased to announce the merger of NOWDx and AEENA Dx.
The combined entity will directly address healthcare’s expansive need for POC and OTC diagnostics at scale. The combination of NOWDx's “Touch to Test” diagnostic platform enabling blood and saliva collection and quantitative reader technology, combined with Aeena's game changing salivary cancer diagnostic platform and collection device, create a continuum of product offerings from a development pipeline which span critical test markets for infectious disease, women's health, drugs of abuse, cardiac markers, and cancer. NOWDx, with capacity to produce over 2 million tests per month from their home base in Springdale, Arkansas, are now well poised to address the over $100 billion dollar global point of care, at-home and hospital-based diagnostics market.
The company's Co-Founder, Kevin Clark, will serve as CSO, and is joined by Rob Weigle, Aeena CEO, who will take over as CEO of the combined entity of NOWDx, and by Aeena's CTO Shivani Nautiyal, Co-Founder of AeenaDx, who will become the combined entity's CTO. Weigle's previously roles include Executive positions at J&J and Baxter, while Nautiyal's resume includes key roles at GRAIL, Illumina and Affymetrix. “I am pleased to be joining such a dynamic team. The market opportunities before the company are phenomenal and I look forward to a bright future for the combined entity” said Weigle, with an extensive background in commercialization of medical devices, FDA submissions and fundraising.
The new entity will carry the name NOWDiagnostics (NOWDx). NOWDx continues to focus on commercialization of its launched tests and development of high impact tests, most notably for Syphilis and Strep. “From its inception, I always believed that NOWDx would play a crucial role in changing healthcare for the future. With the combined entities and C-Suite, we are NOW one step closer” said Co-founder of NOWDx, Co-CEO of New Road Capital and NOWDx Board member Jeremy Wilson. Executive Chairman, Jim Haworth commented “I am excited to see this team come together - not just for the leadership, but also for each individual team member at NOWDx. I am also thrilled about the potential this merger creates for our investors and the millions of patients we will serve around the world.” AeenaDx Board Chair Michele Colucci, who will remain on the Board, adds "The synergies of the combined C-Suite, a robust line of tests going to market, and a healthy R&D pipeline, all serve to ensure NOWDx's leadership and longevity in cutting edge diagnostic innovation, and ensure greater access to healthcare for all."
